Aberdeen Group
BBIO icon

Aberdeen Group’s BridgeBio Pharma BBIO Stock Holding History

Aberdeen Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$19.9M Buy
+301,848
New +$23.5M 0.03% 432
2024
Q2 		– Sell
-142,247
Closed -$4.4M – 947
2024
Q1 		$4.4M Sell
142,247
-142,746
-50% -$4.85M 0.01% 691
2023
Q4 		$11.5M Buy
+284,993
New +$8.56M 0.02% 521

Other funds holding BBIO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Aberdeen Group's BBIO Position: Q3 2026 in Review

Aberdeen Group opened a new position in BridgeBio Pharma (BBIO) in Q3 2026: 301,848 shares worth $19.9M. The stake represents 0.03% of the portfolio and ranks #432 among its holdings. This is a return to the name: Aberdeen Group previously reported a position in BBIO as recently as Q1 2024.

Aberdeen Group first reported a position in BBIO in Q4 2023 and has held it in 3 quarters since. 233 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Aberdeen Group held 301,848 shares of BridgeBio Pharma worth $19.9M as of Q3 2026.
  • BridgeBio Pharma was a new Aberdeen Group position in Q3 2026.
  • BridgeBio Pharma made up 0.03% of Aberdeen Group's portfolio in Q3 2026, its #432 holding.
  • Aberdeen Group first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 3 quarters since.
  • 233 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.